Gilead (GILD) Data Without Riba is Advantage vs AbbVie (ABBV) - Deutsche Bank

January 31, 2014 11:17 AM

Deutsche Bank reiterated a Buy rating on Gilead Sciences (NASDAQ: GILD) with a price target of $132.00. Comments follow new ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found